Cingulate, Inc. ( (CING) ) has released its Q3 earnings. Here is a breakdown of the information Cingulate, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) platform, primarily targeting ADHD and anxiety disorders. Based in Kansas City, the company aims to improve patient outcomes with innovative drug delivery solutions.
In its third-quarter 2025 earnings report, Cingulate Inc. announced several significant corporate developments, including the acceptance of its New Drug Application (NDA) for CTx-1301 by the FDA, a $6 million financing completion, and the appointment of industry veteran Bryan Downey as Chief Commercial Officer.
Key financial highlights for the quarter include a net loss of $7.3 million, driven by increased research and development expenses and general administrative costs. The company also secured a $4.3 million PDUFA fee waiver and entered a commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-1301. The positive Phase 3 results for CTx-1301 were presented at the AACAP Annual Meeting, showcasing its potential in ADHD treatment.
Looking ahead, Cingulate’s management remains focused on disciplined execution and operational efficiency as it prepares for a potential 2026 launch of CTx-1301. The company anticipates needing additional capital to advance commercialization efforts and is committed to creating long-term value for shareholders.